Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

1.

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Pozzilli C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Review.

PMID:
24289844
[PubMed - indexed for MEDLINE]
2.

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.

García-Merino A.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):9-13. doi: 10.1586/ern.13.4. Review.

PMID:
23369054
[PubMed - indexed for MEDLINE]
3.

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.

Flachenecker P.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):15-9. doi: 10.1586/ern.13.1. Review.

PMID:
23369055
[PubMed - indexed for MEDLINE]
4.

Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.

Vermersch P.

Expert Rev Neurother. 2011 Apr;11(4 Suppl):15-9. Review.

PMID:
21449855
[PubMed - indexed for MEDLINE]
5.

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.

Serpell MG, Notcutt W, Collin C.

J Neurol. 2013 Jan;260(1):285-95. doi: 10.1007/s00415-012-6634-z. Epub 2012 Aug 10.

PMID:
22878432
[PubMed - indexed for MEDLINE]
6.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.

PMID:
21456949
[PubMed - indexed for MEDLINE]
7.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
[PubMed - indexed for MEDLINE]
8.

Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.

Koehler J, Amato MP, Oreja-Guevara C, Lycke J.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):61-6. doi: 10.1586/14737175.2013.865881. Review.

PMID:
24289846
[PubMed - indexed for MEDLINE]
9.

Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.

Gold R, Oreja-Guevara C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):55-9. doi: 10.1586/14737175.2013.865880. Review.

PMID:
24289845
[PubMed - indexed for MEDLINE]
10.

Advances in the management of multiple sclerosis spasticity: recent clinical trials.

Fernández O.

Eur Neurol. 2014;72 Suppl 1:9-11. doi: 10.1159/000367616. Epub 2014 Sep 26.

PMID:
25278117
[PubMed - in process]
11.

Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.

Slof J, Gras A.

Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):439-41. doi: 10.1586/erp.12.40. Epub 2012 Jun 8.

PMID:
22681512
[PubMed - indexed for MEDLINE]
12.

Sativex for the management of multiple sclerosis symptoms.

Perras C.

Issues Emerg Health Technol. 2005 Sep;(72):1-4.

PMID:
16317825
[PubMed - indexed for MEDLINE]
13.
14.

[Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].

Wissel J, Entner T.

Wien Klin Wochenschr. 2001;113 Suppl 4:20-4. Review. German.

PMID:
15506048
[PubMed - indexed for MEDLINE]
15.

Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.

Lu L, Pearce H, Roome C, Shearer J, Lang IA, Stein K.

Pharmacoeconomics. 2012 Dec 1;30(12):1157-71. doi: 10.2165/11598470-000000000-00000.

PMID:
23072659
[PubMed - indexed for MEDLINE]
16.

THC:CBD spray and MS spasticity symptoms: data from latest studies.

Rekand T.

Eur Neurol. 2014;71 Suppl 1:4-9. doi: 10.1159/000357742. Epub 2014 Jan 22. Review.

PMID:
24457846
[PubMed - indexed for MEDLINE]
17.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5.

PMID:
24671907
[PubMed - in process]
18.

Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?

Wade D.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):9-14. doi: 10.1586/ern.12.12. Review.

PMID:
22509986
[PubMed - indexed for MEDLINE]
19.

Who benefits most from THC:CBD spray? Learning from clinical experience.

Koehler J.

Eur Neurol. 2014;71 Suppl 1:10-5. doi: 10.1159/000357743. Epub 2014 Jan 22.

PMID:
24457847
[PubMed - indexed for MEDLINE]
20.

Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.

Barnes MP.

Expert Opin Pharmacother. 2006 Apr;7(5):607-15. Review.

PMID:
16553576
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk